Journal of Clinical and Translational Hepatology,
Год журнала:
2024,
Номер
000(000), С. 000 - 000
Опубликована: Окт. 11, 2024
This
review
discussed
experimental
mouse
models
used
in
the
pre-clinical
study
of
liver
fibrosis
regression,
a
pivotal
process
preventing
progression
metabolic
dysfunction-associated
steatohepatitis
to
irreversible
cirrhosis.
These
provide
valuable
resource
for
understanding
cellular
and
molecular
processes
underlying
regression
different
contexts.
The
primary
focus
this
is
on
most
commonly
with
diet-
or
hepatotoxin-induced
fibrosis,
but
it
also
touches
upon
genetic
biliary
atresia
parasite-induced
fibrosis.
In
addition
emphasizing
Abstract
Liver
fibrosis,
a
progressive
condition
resulting
from
chronic
liver
injury,
can
lead
to
cirrhosis
and
hepatocellular
carcinoma.
Nanoparticles
have
emerged
as
promising
tools
for
their
diagnosis
treatment
due
unique
properties.
This
review
highlights
advances
in
lipid‐based
(e.g.,
liposomes,
solid
lipid
nanoparticles),
polymer‐based
nanocapsules,
dendrimers),
inorganic
iron
oxide,
gold
biological
nanoparticles
extracellular
vesicles,
exosomes).
These
enhance
imaging
contrast
MRI
CT,
enabling
non‐invasive
fibrosis
detection,
deliver
drugs
or
gene‐editing
hepatic
stellate
cells
(HSCs)
targeted
therapy.
Extracellular
vesicles
(EVs)
exosomes
also
show
potential
biomarkers
therapeutic
carriers.
However,
challenges
such
limited
targeting
efficiency,
toxicity,
difficulties
clinical
translation
remain.
Future
research
should
focus
on
optimizing
nanoparticle
design,
improving
biocompatibility,
addressing
regulatory
issues
facilitate
application.
Nanoparticle‐based
strategies
hold
great
promise
revolutionizing
management.
